Literature DB >> 25762871

Developmental pharmacokinetics in pediatric populations.

Hong Lu1, Sara Rosenbaum1.   

Abstract

Information on drug absorption and disposition in infants and children has increased considerably over the past 2 decades. However, the impact of specific age-related effects on pharmacokinetics, pharmacodynamics, and dose requirements remains poorly understood. Absorption can be affected by the differences in gastric pH and stomach emptying time that have been observed in the pediatric population. Low plasma protein concentrations and a higher body water composition can change drug distribution. Metabolic processes are often immature at birth, which can lead to a reduced clearance and a prolonged half-life for those drugs for which metabolism is a significant mechanism for elimination. Renal excretion is also reduced in neonates due to immature glomerular filtration, tubular secretion, and reabsorption. Limited data are available on the pharmacodynamic behavior of drugs in the pediatric population. Understanding these age effects provide a mechanistic way to identify initial doses for the pediatric population. The various factors that impact pharmacokinetics and pharmacodynamics mature towards adult values at different rates, thus requiring continual modification of drug dose regimens in neonates, infants, and children. In this paper, the age-related changes in drug absorption, distribution, metabolism, and elimination in infants and children are reviewed, and the age-related dosing regimens for this population are discussed.

Entities:  

Keywords:  cytochrome P450; development; pediatrics; pharmacodynamics; pharmacokinetics

Year:  2014        PMID: 25762871      PMCID: PMC4341411          DOI: 10.5863/1551-6776-19.4.262

Source DB:  PubMed          Journal:  J Pediatr Pharmacol Ther        ISSN: 1551-6776


  92 in total

Review 1.  Population pharmacokinetic studies in pediatrics: issues in design and analysis.

Authors:  Bernd Meibohm; Stephanie Läer; John C Panetta; Jeffrey S Barrett
Journal:  AAPS J       Date:  2005-10-05       Impact factor: 4.009

2.  MATURATION OF RENAL FUNCTION IN CHILDHOOD: CLEARANCE STUDIES.

Authors:  M I Rubin; E Bruck; M Rapoport; M Snively; H McKay; A Baumler
Journal:  J Clin Invest       Date:  1949-09       Impact factor: 14.808

3.  Expression of CYP2D6 in developing human liver.

Authors:  J M Treluyer; E Jacqz-Aigrain; F Alvarez; T Cresteil
Journal:  Eur J Biochem       Date:  1991-12-05

4.  Developmental changes in pharmacokinetics and pharmacodynamics of warfarin enantiomers in Japanese children.

Authors:  H Takahashi; S Ishikawa; S Nomoto; Y Nishigaki; F Ando; T Kashima; S Kimura; M Kanamori; H Echizen
Journal:  Clin Pharmacol Ther       Date:  2000-11       Impact factor: 6.875

5.  Maturation and growth of renal function: dosing renally cleared drugs in children.

Authors:  W L Hayton
Journal:  AAPS PharmSci       Date:  2000

6.  Tramadol disposition in the very young: an attempt to assess in vivo cytochrome P-450 2D6 activity.

Authors:  K Allegaert; B J Anderson; R Verbesselt; A Debeer; J de Hoon; H Devlieger; J N Van Den Anker; D Tibboel
Journal:  Br J Anaesth       Date:  2005-06-10       Impact factor: 9.166

7.  Developmental expression of canalicular transporter genes in human liver.

Authors:  Huey-Ling Chen; Hui-Ling Chen; Yu-Jung Liu; Chun-Hsiang Feng; Chao-Yi Wu; Ming-Kwang Shyu; Ray-Hwang Yuan; Mei-Hwei Chang
Journal:  J Hepatol       Date:  2005-09       Impact factor: 25.083

8.  Development and evaluation of a generic physiologically based pharmacokinetic model for children.

Authors:  Andrea N Edginton; Walter Schmitt; Stefan Willmann
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

Review 9.  Translating pharmacogenetics and pharmacogenomics into drug development for clinical pediatrics and beyond.

Authors:  J Steven Leeder
Journal:  Drug Discov Today       Date:  2004-07-01       Impact factor: 7.851

Review 10.  Children versus adults: pharmacokinetic and adverse-effect differences.

Authors:  Gail D Anderson
Journal:  Epilepsia       Date:  2002       Impact factor: 5.864

View more
  76 in total

1.  Comparison of Amikacin Pharmacokinetics in Neonates With and Without Congenital Heart Disease.

Authors:  Amy L Nguyen; Peter N Johnson; Stephen B Neely; Kaitlin M Hughes; Kris C Sekar; Robert C Welliver; Jamie L Miller
Journal:  J Pediatr Pharmacol Ther       Date:  2021-05-19

2.  Safety and efficacy of rifabutin among HIV/TB-coinfected children on lopinavir/ritonavir-based ART.

Authors:  Holly E Rawizza; Kristin M Darin; Regina Oladokun; Biobele Brown; Babatunde Ogunbosi; Nkiruka David; Sulaimon Akanmu; Oluremi Olaitan; Charlotte Chang; Kimberly K Scarsi; Prosper Okonkwo; Phyllis J Kanki
Journal:  J Antimicrob Chemother       Date:  2019-09-01       Impact factor: 5.790

3.  Efavirenz pharmacokinetics during pregnancy and infant washout.

Authors:  Regis Kreitchmann; Stein Schalkwijk; Brookie Best; Jiajia Wang; Angela Colbers; Alice Stek; David Shapiro; Tim Cressey; Mark Mirochnick; David Burger
Journal:  Antivir Ther       Date:  2019

Review 4.  State-of-the-Art Review on Physiologically Based Pharmacokinetic Modeling in Pediatric Drug Development.

Authors:  Venkata Yellepeddi; Joseph Rower; Xiaoxi Liu; Shaun Kumar; Jahidur Rashid; Catherine M T Sherwin
Journal:  Clin Pharmacokinet       Date:  2019-01       Impact factor: 6.447

Review 5.  A Pathway to Personalizing Therapy for Metastases Using Liver-on-a-Chip Platforms.

Authors:  A S Khazali; A M Clark; A Wells
Journal:  Stem Cell Rev Rep       Date:  2017-06       Impact factor: 5.739

6.  Phase I/IIa Trial of Atorvastatin in Patients with Acute Kawasaki Disease with Coronary Artery Aneurysm.

Authors:  Adriana H Tremoulet; Sonia Jain; Pei-Ni Jone; Brookie M Best; Elizabeth H Duxbury; Alessandra Franco; Beth Printz; Samuel R Dominguez; Heather Heizer; Marsha S Anderson; Mary P Glodé; Feng He; Robert L Padilla; Chisato Shimizu; Emelia Bainto; Joan Pancheri; Harvey J Cohen; John C Whitin; Jane C Burns
Journal:  J Pediatr       Date:  2019-09-24       Impact factor: 4.406

Review 7.  Biological barriers, and the influence of protein binding on the passage of drugs across them.

Authors:  Karolina Wanat
Journal:  Mol Biol Rep       Date:  2020-03-05       Impact factor: 2.316

8.  Personalized pharmacokinetic targeting with busulfan in allogeneic hematopoietic stem cell transplantation in infants with acute lymphoblastic leukemia.

Authors:  Takayuki Takachi; Yuki Arakawa; Hiroyoshi Nakamura; Tomoyuki Watanabe; Yuki Aoki; Junjiro Ohshima; Yoshihiro Takahashi; Masahiro Hirayama; Takako Miyamura; Kanji Sugita; Katsuyoshi Koh; Keizo Horibe; Eiichi Ishii; Shuki Mizutani; Daisuke Tomizawa
Journal:  Int J Hematol       Date:  2019-06-14       Impact factor: 2.490

9.  Antiretroviral drug concentrations in hair are associated with virologic outcomes among young people living with HIV in Tanzania.

Authors:  Zachary J Tabb; Blandina T Mmbaga; Monica Gandhi; Alexander Louie; Karen Kuncze; Hideaki Okochi; Aisa M Shayo; Elizabeth L Turner; Coleen K Cunningham; Dorothy E Dow
Journal:  AIDS       Date:  2018-06-01       Impact factor: 4.177

10.  Pharmacokinetics of Peramivir in an Adolescent Patient Receiving Continuous Venovenous Hemodiafiltration.

Authors:  Ryan C Dillon; Robert Witcher; Jeffrey J Cies; Wayne S Moore; Arun Chopra
Journal:  J Pediatr Pharmacol Ther       Date:  2017 Jan-Feb
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.